Home > Insider Trading > Filing (0001179110-13-003272)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1113481	Medicines Co	MDCO	Pharmaceutical Preparations (2834)	043324394

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1318459	Michael Paul Antinori	8 Sylvan Way Parsippany NJ 07054	Sr. Vp & General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2013-02-19	569	$31.81	45,469	No	4	S	Direct
Common Stock	Acquisiton	2013-02-20	6,500	$18.27	51,969	No	4	M	Direct
Common Stock	Disposition	2013-02-20	6,500	$32.50	45,469	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option (right to buy)	Disposition	2013-02-20	6,500	$0.00	6,500	$18.27

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2015-11-30	No	4	M	Direct

Footnotes

Represents the number of shares sold to cover the tax expense associated with the vesting of restricted shares held by Mr. Antinori pursuant to his Restricted Stock Agreements with the Company.
The range of prices for the transactions reported on this line is between $31.77 and $31.88 per share. The price reported above reflects the weighted average sales price. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
The common stock sales reported on this line of the Form 4 were effected pursuant to a Rule 10b5-1 program adopted by Mr. Antinori on August 10, 2012.
As of 2/20/2013, the original grant (12,500 shares granted on 11/30/2005) was fully vested. After the exercise of the options reported hereby, as of 2/20/2013, all shares covered by this option have been exercised.